Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRevolution Beauty Regulatory News (REVB)

Share Price Information for Revolution Beauty (REVB)

Share Price is delayed by 15 minutes
Get Live Data
4.56    0.28 (6.54%)
Bid:
4.40
Ask:
4.54
Spread: 0.14 (3.182%)
Market Cap: £39.66m
REVB Live PriceLast checked at - London Stock Exchange

Intraday Revolution Beauty Share Chart

Trading Update

13 May 2025 07:00

RNS Number : 3508I
Revolution Beauty Group PLC
13 May 2025
Β 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"), AND IS DISCLOSED IN ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 17 OF MAR.Β 

FOR IMMEDIATE RELEASE

13 May 2025

Revolution Beauty Group Plc

("Revolution" or the "Company")

TRADING UPDATE

Revolution Beauty Group, the multi-channel mass beauty brand, is today providing an update for the year ended 28 February 2025 ("FY25") and an update on the FY26 outlook and certain other matters.

FY25 trading update

FY25 was a transformational year for Revolution Beauty, during which it has discontinued over 6,000 SKUs to create a scalable and profitable foundation for future growth. The Company continues to transition its global retailers onto this core set of products.

Revenues for FY25 closed at approximately Β£141.6m, down 26% year-on-year reflecting the rationalisation of the product and brand portfolio. Softness in the US market and on digital channels, as previously reported, continued into January and February 2025.

The Company expects to report FY25 underlying adjusted EBITDA of between Β£6.0m and Β£6.5m. Adjusting items included an adjustment for stock provision charges related to non-strategic stock of Β£9.2m. Cash balances at the end of February 2025 were Β£5.7m and net debt was Β£26.3m with a revolving credit facility of Β£32m. Gross inventories reduced from Β£60m to Β£33m at 28 February 2025.

The FY25 revenue and EBITDA above remain subject to audit and any adjustments that may further be required as part of the audit process.

Current trading and FY26 outlook

The Company had planned for double digit net sales declines to continue into the first quarter of FY26, driven by the remaining impact of the SKU discontinuations, but March and April have been softer than planned due primarily to performance weakness in pure play digital retailers (excluding Amazon that continues to grow significantly) and weakened consumer confidence impacting USA performance. Management considers both impacts as short to medium term.

Management is however encouraged by sales from the rejuvenated New Product Development SKUs launched in February 2025 and plans to build on this success by expanding the digital fast-track program in the second half of FY26.Β 

A recent Kantar study has also confirmed that consumer consideration to buy Revolution Beauty has significantly increased over the last 12 months in the UK, suggesting that the focussed brand activity is improving brand health and competitiveness for the future. In the UK the brand is now fourth in the ranking of considered brands for make-up, up from sixth 12 months ago. Management plans to carefully invest marketing in core markets to drive sales conversion from this encouraging progress.

The Company has also landed its first orders for its new RELOVE budget make-up brand designed for value and the grocery channel and is expanding efforts to accelerate this profitable brand at pace across the year. The Company has expanded its retail distribution footprint for our master brand "Revolution" into major global retailers including Walmart and DM Germany and supplemented its make-up brand with a new Revolution skincare range targeted at the brands core Gen Z customer. An innovative mascara product Wrap Lash has also launched in the last few weeks.

Given the slower start to the year than planned, Management continues to reduce costs in line with performance and to capture the benefits of having a simplified product and brand portfolio.

With continued focus on cost and inventory management, Management expects the impact of lower sales on FY26 EBITDA to be significantly mitigated.

USA tariffs - potential impact

The Company very much welcomes the announcement of 11 May 2025 regarding imports to the USA from China which will be subject to much lower tariffs than previously proposed. In FY25, 23% of Company sales were generated in the US market with approximately 60% of the Company's products sold in the USA being manufactured in China.

Therefore, it is expected that the increase in tariffs on goods imported into the US from China will have a consequently lower impact on the Company's cost of goods sold in the market than previously modelled, but it will continue to assess this in light of yesterday's announcement.

The Company is benefitting from having imported significant volumes into the USA before the tariff charges were significantly increased and has suspended the import of inventory into the USA until trade discussions between USA and China provided more clarity. Following yesterday's announcement, the Company has been able to authorise shipments where NPD launches dictate. The Company is engaging with all its retail partners to assess the need for cost price increases as a result of the tariff charge increases whilst seeking to maintain Revolution Beauty's competitive positioning in the USA.

Review of funding options

Revolution Beauty has a significant global distribution footprint in high street retailers and on renowned digital platforms, with the improved brand metrics and accelerating NPD pipeline, Management remains confident in the future growth potential of the Company.Β 

While the Board has confidence in the future medium-term prospects for the Company, cash management has been tight and it is clear that the delivery of the strategy will benefit from a more robust capital structure with additional capital to invest into the Company. As such, the Board has been actively reviewing the Company's funding structure.

Revolution Beauty's fully Β£32m revolving credit facility ("RCF") runs to October 2025. The Company's banking partners remain supportive of the Company, and it has been in active and constructive dialogue with its banking partners regarding amending and extending the current RCF to provide adequate flexibility for the Company going forward.

Β 

Β 

For further information, please contact:

Revolution Beauty Group Plc

Β 

Β 

Colin Henry, Interim CEO

Neil Catto, CFO

Β 

Β 

via Headland Consultancy

Panmure Liberum LimitedΒ (NOMAD and Joint Broker)

Β 

+44 (0)20 3100 2222

Bidhi Bhoma / Dru Danford / Edward Thomas / John More

Β 

Β 

Β 

Zeus (Joint Broker) Benjamin Robertson / Nick Cowles / Jordan Warburton

Β 

Β 

+44 (0)161 831 1512

Β 

Β 

Media enquiries:

Headland Consultancy

Matt Denham / Antonia Pollock

Revolutionbeauty@headlandconsultancy.com

Β 

Β 

Β 

+44 (0)75 518 25496 / +44 (0)77 899 54356

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTFFFVFELIFLIE
Date   Source Headline
30th Mar 20237:00 amRNSUpdate on timing of FY22 Results and Financing
7th Mar 20232:00 pmRNSRevised deferred consideration for Medichem
21st Feb 20237:00 amRNSUpdate on FY22 Audit
13th Jan 20237:00 amRNSOutcome of Independent Investigation
16th Dec 20222:35 pmRNSDirectorate Change
28th Nov 20222:24 pmRNSHolding(s) in Company
28th Nov 20227:00 amRNSAppointment of CEO
25th Nov 20224:27 pmRNSTR-1: Standard notification of major holdings
9th Nov 20229:05 amRNSDirectorate Change
27th Oct 20225:30 pmRNSSuspended Companies Notice – Deletions
14th Oct 20227:00 amRNSUpdate on Independent Investigation
23rd Sep 20227:00 amRNSFurther update on the Group’s audit
23rd Sep 20227:00 amRNSFurther update on the Group’s audit
7th Sep 20227:00 amRNSTR-1: Standard notification of major holdings
1st Sep 20227:30 amRNSSuspension - Revolution Beauty Group plc
30th Aug 20227:00 amRNSUpdate on Publication of Final Results
19th Aug 20222:30 pmRNSFurther update on the Group’s audit
17th Aug 20226:20 pmRNSTR-1: Standard notification of major holdings
17th Aug 20226:15 pmRNSTR-1: Standard notification of major holdings
17th Aug 20226:00 pmRNSTR-1: Standard notification of major holdings
17th Aug 20227:05 amRNSStrategic Investment in Revolution Beauty Group
17th Aug 20227:00 amRNSTR-1: Standard notification of major holdings
17th Aug 20227:00 amRNSTR-1: Standard notification of major holdings
12th Aug 20221:55 pmRNSTR-1: Standard notification of major holdings
11th Aug 20224:41 pmRNSSecond Price Monitoring Extn
11th Aug 20224:35 pmRNSPrice Monitoring Extension
11th Aug 202211:05 amRNSUpdate on the Group’s audit
11th Aug 202210:10 amRNSTR-1: Standard notification of major holdings
5th Aug 20221:20 pmRNSTR-1: Standard notification of major holdings
3rd Aug 20223:45 pmRNSTR-1 Standard notification of major holdings
2nd Aug 20227:00 amRNSTrading update and change to results date
30th Jun 20227:00 amRNSCorporate Broker Appointment and Notice of Results
17th Jun 20227:00 amRNSNOTIFICATION OF MAJOR HOLDINGS
12th May 20227:00 amRNSAppointment of Chief Financial Officer
11th May 202211:40 amRNSHolding(s) in Company
6th May 20227:00 amRNSFull Year Trading Update
25th Feb 20227:00 amRNSAcquisition
23rd Feb 20225:50 pmRNSHolding(s) in Company
26th Jan 20227:00 amRNSTrading Update
24th Nov 20217:00 amRNSInterim Results
27th Oct 20217:00 amRNSAcquisition of Medichem Manufacturing
27th Sep 20217:00 amRNSH1 Trading Update and Notice of Results
20th Aug 202111:47 amRNSIssue of Shares under Share Incentive Plan & TVR
23rd Jul 202112:08 pmRNSImplementation of Long Term Incentive Plan
22nd Jul 20215:35 pmRNSNotification of Major Holdings
21st Jul 20217:00 amRNSNotification of Major Holdings
20th Jul 20215:59 pmRNSDirector Dealing
19th Jul 20217:00 amRNSAdmission to AIM and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.